Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Disaggregated Revenues

The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands):



	Three Months Ended March 31, 2019
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	2,189	$	1,530	$	599	$	4,318
Consumables	8,176		3,244		726		12,146
In vitro diagnostic kits	430		1,812		72		2,314
Total product revenue	10,795		6,586		1,397		18,778
Service revenue	1,794		614		164		2,572
Total product and service revenue	12,589		7,200		1,561		21,350
Collaboration revenue	6,338		—		—		6,338
Total revenues	$	18,927	$	7,200	$	1,561	$	27,688



	Three Months Ended March 31, 2018
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	2,686	$	1,485	$	503	$	4,674
Consumables	6,160		2,377		820		9,357
In vitro diagnostic kits	681		1,397		88		2,166
Total product revenue	9,527		5,259		1,411		16,197
Service revenue	1,261		499		88		1,848
Total product and service revenue	10,788		5,758		1,499		18,045
Collaboration revenue	5,040		—		—		5,040
Total revenues	$	15,828	$	5,758	$	1,499	$	23,085

Contract balances and remaining performance obligations

Contract liabilities are comprised of the current and long-term portions of deferred revenue of $10.7 million and $11.5 million as of March 31, 2019 and December 31, 2018, respectively, and within customer deposits of $5.9 million and $8.2 million as of March 31, 2019 and December 31, 2018, respectively, on the condensed consolidated balance sheets. Total contract liabilities decreased by $3.1 million for the three months ended March 31, 2019 as a result of cash payments received of $4.9 million related to our collaborations and service contracts, offset by the recognition of previously deferred revenue of $7.9 million for the completion of certain performance obligations during the period. The Company did not record any contract assets as of March 31, 2019.

Unsatisfied or partially unsatisfied performance obligations related to collaboration agreements as of March 31, 2019 were $9.7 million and are expected to be completed over the period of each collaboration agreement, through December 2019. Performance obligations related to product and service contracts as of March 31, 2019 were $7.0 million and are expected to be completed over the term of the related contract, through February 2024.